BB Biotech AG (0JYO) Posts CHF 430 Million H1 2026 Profit and Updates Dividend Policy to 3–5% Yield

Robust H1 2026 Performance Driven by Portfolio Gains

BB Biotech AG achieved a strong recovery in investment results during the first half of 2026, posting a net profit of CHF 430 million for the period ending 30 June 2026, a notable improvement from the CHF 341 million loss recorded in H1 2025. This positive turnaround reflects the appreciation of the company’s holdings in innovative pharmaceutical and biotechnology firms. As an investment company, BB Biotech's gains and losses correspond directly to the valuation changes of its underlying portfolio rather than operational revenues or trading activities.

The second quarter exhibited even stronger performance, with BB Biotech recording a CHF 451 million gain from April to June 2026, contrasting sharply with a CHF 100 million loss in Q2 2025. This quarter-on-quarter improvement highlights significant upward revaluation in the biotech and pharmaceutical sectors, especially among BB Biotech’s US and Western European investments. As one of the world’s largest investors in innovative drug development, BB Biotech benefits materially from sector-wide valuation shifts and clinical trial outcomes across its portfolio.

Dividend Policy Overhaul Introduces Yield-Based Framework

Effective from the 2026 financial year, BB Biotech AG has revamped its dividend policy, replacing the previous fixed payout approach with a flexible target annual dividend yield of 3–5%. This strategic shift allows dividend distributions to adjust in line with the company’s share price and portfolio valuation, providing management with greater flexibility to align payouts with net asset value and shareholder returns.

The new yield-based policy balances the interests of income-focused investors with the need to retain capital for reinvestment in promising pharmaceutical and biotech opportunities. The 3–5% yield target aligns with dividend expectations for large-cap investment companies while granting management discretion to respond to market conditions and portfolio performance. This change was disclosed alongside the interim results and reflects management’s capital allocation strategy amid current market dynamics.

Focused Portfolio and Investment Approach in Developed Markets

BB Biotech AG is a specialist investment company focused exclusively on innovative drug developers and biotechnology enterprises. Its portfolio centers on companies headquartered primarily in the United States and Western Europe, regions that dominate early-to-late stage pharmaceutical innovation. This geographic and sector concentration positions BB Biotech as a pure-play investment vehicle for exposure to life sciences innovation. The Board of Directors, with extensive experience, sets the investment strategy and portfolio guidelines.

Investment decisions are executed by Bellevue Asset Management AG’s seasoned team based in Zurich, Switzerland. This team conducts comprehensive research and due diligence to identify and evaluate potential investments in pharmaceutical and biotech companies. Delegating investment management to a specialist asset manager with deep sector expertise enables BB Biotech’s Board to focus on strategic oversight while the operational team maintains detailed knowledge of portfolio companies, clinical developments, regulatory changes, and competitive dynamics. BB Biotech’s scale as a leading investor in this sector enhances its market influence and information access, potentially improving returns.

Stock Exchange Listings and Shareholder Market Access

BB Biotech AG is listed on multiple exchanges, offering shareholders diverse trading options and liquidity. It trades on Frankfurt’s regulated market under the Prime Standard segment, a prestigious designation for established companies. Additionally, BB Biotech is listed on the Milan and SIX Swiss exchanges, providing European investors direct access. The company’s ISIN is CH0038389992, and its German securities identification number (WKN) is A0NFN3. Multiple listings typically enhance liquidity and reduce bid-ask spreads for investors.

Registered in Schaffhausen, Switzerland, BB Biotech’s administrative office is located at Schwertstrasse 6, 8200 Schaffhausen. Switzerland’s established investment management infrastructure and regulatory framework underpin the company’s domicile. Bellevue Asset Management AG, responsible for investment management, is headquartered at Theaterstrasse 12, 8001 Zurich, situating both entities within Switzerland’s main financial centers. This structure supports efficient investment management and regulatory compliance.

Sector Risks and Pharmaceutical Development Challenges

BB Biotech’s concentrated exposure to the innovative pharmaceutical and biotechnology sector entails inherent risks alongside growth potential. The biotech industry faces high clinical trial failure rates, with many compounds not reaching regulatory approval or commercialization. Portfolio companies are vulnerable to trial failures, adverse regulatory outcomes, patent expiries, competitive product launches, and changes in healthcare reimbursement policies. BB Biotech’s returns depend heavily on the success of multiple portfolio companies navigating these risks, meaning sector-wide setbacks or adverse clinical developments could significantly impact the company’s net asset value and reported profits.

Additionally, regulatory and political factors can materially influence the sector over time. Changes in pharmaceutical pricing, accelerated approval pathways, patent protections, and research funding can reshape the investment landscape. Currency fluctuations also affect BB Biotech’s reporting in Swiss francs, as most holdings are denominated in US dollars and euros. Geopolitical tensions, especially between the US and Europe, may impact scientific collaboration and portfolio valuations. Investors should understand that BB Biotech’s performance is significantly influenced by external factors beyond management’s control within the biotech and pharmaceutical sectors.

Interim Report Access and Investor Relations

BB Biotech AG has published its interim report as of 30 June 2026 on its official website at www.bbbiotech.ch. The report includes detailed consolidated financial statements, management commentary, and insights into the company’s business activities and investment performance for H1 2026. Shareholders and prospective investors can review the full financial position, portfolio composition, and management’s market outlook. Publishing interim reports is a standard practice for listed investment companies, ensuring transparency for equity holders evaluating company progress.

Investor relations inquiries can be directed to Dr. Christian Koch, Head of the BB Biotech Team, or the Head of Investor Relations at [email protected]. Media contacts include Rachael Burri at [email protected] and Fabienne Tresch at [email protected]. General contact details for Bellevue Asset Management AG are Theaterstrasse 12, 8001 Zurich, Switzerland, with telephone +41 44 267 67 00. These channels provide shareholders with direct access to information on BB Biotech’s investment strategy, portfolio updates, and corporate governance.

Regulatory Disclosure and Inside Information Compliance

The interim results and dividend policy update were released as an ad hoc announcement under Article 53 of the SIX Listing Rules and classified as inside information pursuant to Article 17 of the EU Market Abuse Regulation (No 596/2014). This designation confirms that regulators and legal advisors deemed the information material for investor decision-making. The ad hoc disclosure ensures all market participants receive the information simultaneously, promoting fairness and transparency and preventing selective disclosures.

The announcement was distributed via EQS News, a service specializing in regulated financial disclosures compliant with German and international regulations. BB Biotech’s LEI Code is 391200MBZQNPFHIVKO34. The company assumes full responsibility for the accuracy and completeness of the disclosed information. The 24 July 2026 disclosure date and interim report publication comply with listing rules applicable to Frankfurt Prime Standard, Milan, and SIX exchanges.

Impact of Dividend Policy Change on Future Shareholder Returns

Transitioning from a fixed dividend to a 3–5% yield target affects the consistency and amount of future shareholder distributions. Previously, dividends were predetermined regardless of share price fluctuations. Under the new yield-based approach, dividend payments will vary with BB Biotech’s valuation. When share prices rise significantly, the 3–5% yield target may lead to lower absolute dividends per share compared to the fixed policy; conversely, during price declines, it could support higher dividend payouts. This flexibility enables management to balance income distribution with capital preservation and reinvestment opportunities.

The timing of this policy update, announced alongside a strong interim profit of CHF 430 million, signals management’s confidence in sustaining both capital growth and dividend income. The 3–5% yield range aligns with common European investment company practices, balancing shareholder returns with capital retention for portfolio management. Investors familiar with the prior fixed dividend should monitor forthcoming dividend announcements to evaluate the policy’s application and resulting payments. This governance change is a significant development warranting close attention from income-focused investors and those assessing BB Biotech’s total return potential.